Pipeline

Multi-year, multi-program research collaboration, option and license agreement addressing broad therapeutic area of cardiovascular diseases.  The partnership will leverage Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule compound library and R&D capabilities to  identify and advance novel therapeutics.

Research and development partnership to identify drug candidates using Dewpoint’s discovery platform related to biomolecular condensates to treat insulin resistance. The partnership brings together Novo Nordisk’s global leadership in treating diabetes and metabolic diseases with Dewpoint’s groundbreaking discovery and AI technology platform to identify modulators of biomolecular condensates.

Strategic R&D collaboration to advance Dewpoint’s leading oncology pipeline programs of condensate modifying therapeutics (c-mods) to Investigational New Drug Applications (“INDs”) using Evotec’s industry-leading fully integrated data-driven platform (INDiGO).

Partnership to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify’s programmable chemistry platform against condensate targets of interest in Dewpoint’s oncology and neurodegeneration pipeline.

Collaboration to advance a small molecule condensate modulator (c-mod) targeting TDP-43, with the potential to address the underlying pathology of >97% of ALS patients. The partnership will leverage Dewpoint’s platform and condensate science expertise and Mitsubishi Tanabe Pharma Corporation (MTPC)’s unparalleled expertise in ALS therapeutic development. Upon achieving predetermined milestones, MTPC has an option for a global license to develop and commercialize the novel TDP-43 c-mod.

Strategic partnership combining Concert AI’s clinico-genomic data sets with Dewpoint’s AI/ML-powered discovery and development platform to optimize patient stratification for Dewpoint’s oncology c-mod pipeline. The first phase of the partnership will drive development of the lead oncology program targeting beta catenin for Wnt-driven solid tumors.